Article
Can activated recombinant factor VII be used to postpone the exposure of infants to factor VIII until after 2 years of age?
Haemophilia : the official journal of the World Federation of Hemophilia - 1 Jul 2005
Rivard G E, Lillicrap D, Poon M C, Demers C, Lépine M, St-Louis J, Warner M
Abstract excerpt
Two retrospective studies have suggested that exposure to factor VIII (FVIII) in early infancy is associated with an increased risk of FVIII inhibitor development. We prospectively studied 11 infants who needed replacement therapy for bleeding episodes before the age of 2 years. They received activated recombinant factor VII (rFVIIa) concentrate on demand, with the intention of postponing their first exposure to...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
